Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Abstract Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not b...
Main Authors: | Manali Mukherjee, Melanie Kjarsgaard, Katherine Radford, Chynna Huang, Richard Leigh, Delbert R. Dorscheid, Catherine Lemiere, Louis-Philippe Boulet, Susan Waserman, James Martin, Parameswaran Nair |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0337-2 |
Similar Items
-
Underestimation of airway luminal eosinophilia by quantitative sputum cytometry
by: Melanie Kjarsgaard, et al.
Published: (2021-07-01) -
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
by: Ashkenazi M, et al.
Published: (2018-06-01) -
A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01) -
Serum free IgE guided dose reduction of omalizumab: a case report
by: Yasuhiro Gon, et al.
Published: (2017-08-01) -
Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01)